research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
Search
for
Sort by
Research
270-300 / 320 results 
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research A New Era for Alopecia Areata: New Treatments and Improved Knowledge of the Condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Efficacy in Subgroups Related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Spotlight in Plastic Surgery: October 2022
Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
research Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Impact of Baricitinib on Work Productivity and Indirect Costs in Adult Patients with Atopic Dermatitis: A Meta-Analysis of Clinical Trials
Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
research Real-World Experience of Efficacy and Safety of Baricitinib in Korean Patients with Severe Alopecia Areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Single Best Answers for Hematology Specialist Trainees
The document provides 70 multiple choice questions to improve haematology skills.
research Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
research Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Distribution of SALT Scores by Therapeutic Response in Patients with Severe Alopecia After 52 Weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Section 2: Single Best Answer Questions 51–120
The document tests knowledge and decision-making in hematology through multiple-choice questions.
research A Rare Case of Isolated Pulmonary Involvement in Lymphoid Variant Hypereosinophilic Syndrome
A man with a rare lung-focused form of hypereosinophilic syndrome improved with steroid treatment.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Effects of the RV3466F Lotion on Female Telogen Effluvium: Results from a 16-Week, Multi-Centric, Controlled, Randomized Trial
RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
research Atopic Dermatitis And Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research Molecular Docking Studies and ADME-Tox Prediction of Phytocompounds from Merremia Peltata as a Potential Anti-Alopecia Treatment
The compound 16 from the Merremia peltata plant could potentially be a good treatment for hair loss (alopecia) due to its strong activity and favorable skin absorption.
research Skin Regeneration with Conical and Hair Follicle Structure of Deep Second-Degree Scalding Injuries via Combined Expression of the EPO Receptor and Beta Common Receptor by Local Subcutaneous Injection of Nanosized rhEPO
Local injections of nanosized rhEPO can speed up skin healing and improve quality after deep second-degree burns.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Methotrexate Dose Has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial
Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
research What’s Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses
Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Mesenchymal Stem Cells: Scientific Support for Multiple Therapies
Mesenchymal Stem Cells (MSCs) are promising for multiple therapies, but more research is needed to fully understand and optimize their use.